Qiagen N.V. (NYSE:QGEN) is reporting second quarter financial results on Tuesday 4th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, QGEN is expected to report 2Q20 income of $ 0.46 per share from revenue of $ 425.82 million.
For the full year, analysts anticipate top line of $ 1713.82 million, while looking forward to income of $ 1.80 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,572.00 million ~ $ 1,587.00 million, where as bottomline are predicted in a range of $ 1.52 ~ $ 1.54 per share
Click Here For More Historical Outlooks Of Qiagen N.V.
Previous Quarter Performance
Qiagen N.V. reported income for the first quarter of $ 0.34 per share, from the revenue of $ 372.10 million. The quarterly earnings swell 25.93 percent while revenues extended 6.24 percent compared with the same quarter last year.
According to street consensus, QGEN was expected to report 1Q20 income of $ 0.27 per share from revenue of $ 344.87 million. The bottom line results beat street analysts by $ 0.07 or 25.93 percent, at the same time, top line results outshined analysts by $ 27.23 million or 7.90 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Qiagen N.V.
Stock Performance
According to the previous trading day, closing price of QGEN was $ 48.93, representing a 95.41 % increase from the 52 week low of $ 25.04 and a 4 % decrease over the 52 week high of $ 50.97.
The company has a market capital of $ 11.16 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”QGEN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
